Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN

Tafaghodi, Mohsen; Khamesipour, Ali; Jaafari, Mahmoud Reza

doi:10.1007/s00436-010-2176-4

Cited by 52 publications

(35 citation statements)

References 75 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…56,57 This is the first reported study utilizing a nanoparticle delivery system approach in developing a therapeutic vaccine against Chagas disease. Our findings of parasite reduction, but not elimination, are similar to the majority of Chagas disease vaccine studies.…”

Section: Discussionmentioning

confidence: 99%

A therapeutic nanoparticle vaccine againstTrypanosoma cruziin a BALB/c mouse model of Chagas disease

Barry

Wang

Jones

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Chagas disease, caused by Trypanosoma cruzi, results in an acute febrile illness that progresses to chronic chagasic cardiomyopathy in 30% of patients. Current treatments have significant side effects and poor efficacy during the chronic phase; therefore, there is an urgent need for new treatment modalities. A robust T H 1-mediated immune response correlates with favorable clinical outcomes. A therapeutic vaccine administered to infected individuals could bolster the immune response, thereby slowing or stopping the progression of chagasic cardiomyopathy. Prior work in mice has identified an efficacious T. cruzi DNA vaccine encoding Tc24. To elicit a similar protective cell-mediated immune response to a Tc24 recombinant protein, we utilized a poly(lactic-co-glycolic acid) nanoparticle delivery system in conjunction with CpG motif-containing oligodeoxynucleotides as an immunomodulatory adjuvant. In a BALB/c mouse model, the vaccine produced a T H 1-biased immune response, as demonstrated by a significant increase in antigen-specific IFNg-producing splenocytes, IgG2a titers, and proliferative capacity of CD8 C T cells. When tested for therapeutic efficacy, significantly reduced systemic parasitemia was seen during peak parasitemia. Additionally, there was a significant reduction in cardiac parasite burden and inflammatory cell infiltrate. This is the first study demonstrating immunogenicity and efficacy of a therapeutic Chagas vaccine using a nanoparticle delivery system.

show abstract

Section: Discussionmentioning

confidence: 99%

A therapeutic nanoparticle vaccine againstTrypanosoma cruziin a BALB/c mouse model of Chagas disease

Barry

Wang

Jones

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…[16] There are basically two possible ways to take advantage of MPs/NPs for immunization purposes. One way consists of 70 encapsulating the antigen inside liposomes [17,18] or inside organic biodegradable polymers, such as poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), [19][20][21][22][23][24] disulfide cross-linked polyacrylates, [25] or polysaccharides, such as pullulan [26] and chitosan. [27][28][29] This way, the particles can easily reach cytosol, where they are degraded, thus releasing the antigen.…”

Section: Introductionmentioning

confidence: 99%

Carbon nanotube-protein carriers enhance size-dependent self-adjuvant antibody response to haptens

Parra

Abad‐Somovilla

Mercader

et al. 2013

Journal of Controlled Release

View full text Add to dashboard Cite

Carbon nanotubes (CNTs) are nanomaterials with interesting emerging applications. Their 25 properties makes CNTs excellent candidates for use as new nanovehicles in drug delivery, immunization and diagnostics. In the current study, we assessed the immune-response-amplifying properties of CNTs to haptens by using azoxystrobin, the first developed strobilurin fungicide, as a model analyte. An azoxystrobin derivative bearing a carboxylated spacer arm (hapten AZc6) was covalently coupled to bovine serum albumin (BSA), and the resulting BSA-AZc6 conjugate was 30 covalently linked to four functionalized CNTs of different shapes and sizes, varying in diameter and length. These four types of CNT-based constructs were obtained using efficient, fast, and easy functionalization procedures based on microwave-assisted chemistry. New Zealand rabbits and BALB/c mice were immunized with BSA-AZc6 alone and with the four CNT-BSA-AZc6 constructs, both with and without Freund's adjuvant. The IgG-type antibody responses were assessed 35 in terms of the titer and affinity, paying special attention to the relationship between the immune response and the size and shape of the employed CNTs. Immunization with CNT-BSA-AZc6 resulted in enhanced titers and excellent affinities for azoxystrobin. More important, remarkable IgG responses were obtained even in the absence of an adjuvant, thus proving the self-adjuvanting capability of CNTs. Immunogens were able to produce strong anti-azoxystrobin immune responses 40 in rabbits even when administered at a BSA-AZc6 conjugate dose as low as 0.05 g. The short and thick CNT-BSA-AZc6 construct produced the best antibody response under all tested conditions.

show abstract

“…and DNA [28][29][30][31]. Some nanoparticles are deposited within mitochondria and impair oxidative stress pathway [28][29][30][31].…”

Section: Application Of Nano Drugs In Treatment Of Leishmaniasismentioning

confidence: 99%

“…On the other hand, adenosine triphosphate (ATP) synthesis is inhibited when mitochondrial proteins are damaged [28][29][30][31]. Additionally, antimicrobial nanoparticles can impair glycoprotein and lipophosphoglycan molecules, which are responsible for infectivity of bacteria and parasites [31]. Another mechanism is ion release from nanoparticles [31].…”

Section: Application Of Nano Drugs In Treatment Of Leishmaniasismentioning

confidence: 99%

“…Additionally, antimicrobial nanoparticles can impair glycoprotein and lipophosphoglycan molecules, which are responsible for infectivity of bacteria and parasites [31]. Another mechanism is ion release from nanoparticles [31]. These ions interact with cysteine-containing proteins, and inhibit protein functions [31][32][33].…”

Section: Application Of Nano Drugs In Treatment Of Leishmaniasismentioning

confidence: 99%

See 1 more Smart Citation

Application of Nano Drugs in Treatment of Leishmaniasis

Shahcheraghi¹

2016

Glob J Infect Dis Clin Res

View full text Add to dashboard Cite

Objective: Leishmaniasis is endemic in 88 countries with incidence rate of 1.5-2 million; the most common form of leishmaniasis is cutaneous leishmaniasis (CL) with 1.5 million new cases per year. Correct diagnosis and characterization of the particular parasite is important for evaluating prognosis and prescribing appropriate treatment. The current management of leishmaniasis is drug treatment of patients, to alleviate disease and vector control to reduce its transmission. Also, current treatments for visceral leishmaniasis are unsatisfactory because of their toxicity, resistance and high cost. The purpose of the present study was to review the application of nano drugs in treatment of leishmaniasis. Materials and Methods:it was used as source of research the following databases: MEDLINE, Cochrane Library, Scielo, PubMed and the database of CAPES.Results: It has been proved nanosilver particles with highly small sizes, have a good penetration into the cutaneous lesions and a good efficacy on leishmaniasis.anti-leishmanial therapy [14][15][16][17]. Although glucantime is commonly used for the treatment of leishmaniasis, it has some side effects including increased liver enzymes and electrocardiogram changes [17]. In addition, the drug is expensive, the injection is painful, and research shows that resistance of parasite to glucantime is growing in different parts of the world [17][18][19][20]. The use of nanotechnology is ever-expanding in today's technologically advanced world. This form of technology has many advantages over existing ones in many fields and medicine is one of them [20]. There are numerous devices and mechanisms developed with the aid of nanotechnology that can help cure diseases/disorders in a much better and more efficient manner [21]. The usefulness of nanotechnology can especially be seen in the treatment of infectious diseases [21,22]. This review has investigated the treatment of leishmaniasis by nano drugs. Nano drugs against leishmaniasisNanotechnology must be applied for curing infectious disease like leishmaniasis [22]. Many drugs have been made and are still being discovered, but the protozoan re-emerges showing drug resistance to the effective medications [23]. Nanotechnology has just managed to show its promise in developing a liposomal formulation called amphotericin B for leishmaniasis but has serious side effects and is not cost effective in developing countries [23][24][25]. Initial, nanodelivery systems for delivering chemotherapeutics were nanodisks impregnanted with amphotericin B, polymericnanoparticle loaded with pentamidine, primaquine, and niosomes, which still need validation at the clinical level [25][26][27][28]. There is an urgent need to take up assignments to use effective nanotechnology devices in combating this infectious disease [25][26][27][28].Different mechanisms were proposed for antimicrobial property of nanoparticles [28]. One mechanism is binding of nanoparticle to sulfur/ phosphorus-containing biomolecules such as proteins and DNA, which leads to...

show abstract

Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN

Cited by 52 publications

References 75 publications

A therapeutic nanoparticle vaccine againstTrypanosoma cruziin a BALB/c mouse model of Chagas disease

A therapeutic nanoparticle vaccine againstTrypanosoma cruziin a BALB/c mouse model of Chagas disease

Carbon nanotube-protein carriers enhance size-dependent self-adjuvant antibody response to haptens

Application of Nano Drugs in Treatment of Leishmaniasis

Contact Info

Product

Resources

About